Recommended Readings: George Q. Daley, M.D., Ph.D.

Friday Lecture Series

Maclyn McCarty Memorial Lecture

Reprogramming Cell Identity

George Q. Daley, M.D., Ph.D., Samuel E. Lux, IV Professor of Hematology and

director,Stem Cell Transplantation Program, Boston Children’s Hospital;

investigator, Howard Hughes Medical Institute

October 18, 2013

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

Recommended Readings

Cherry, A. B. C., & Daley, G. Q. (2012). Reprogramming cellular identity for regenerative medicine. Cell, 148(6), 1110-1122

Morris, S. A., & Daley, G. Q. (2013). A blueprint for engineering cell fate: Current technologies to reprogram cell identity. Cell Research, 23(1), 33-48

Müller, L. U. W., Milsom, M. D., Harris, C. E., Vyas, R., Brumme, K. M., Parmar, K., . . . Williams, D. A. (2012). Overcoming reprogramming resistance of fanconi anemia cells. Blood, 119(23), 5449-5457

Onder, T. T., Kara, N., Cherry, A., Sinha, A. U., Zhu, N., Bernt, K. M., . . . Daley, G. Q. (2012). Chromatin-modifying enzymes as modulators of reprogramming. Nature, 483(7391), 598-602

Robinton, D. A., & Daley, G. Q. (2012). The promise of induced pluripotent stem cells in research and therapy. Nature, 481(7381), 295-305

Zhang, J., Nuebel, E., Daley, G. Q., Koehler, C. M., & Teitell, M. A. (2012). Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell, 11(5), 589-595


Recommended Readings: Barry S. Coller M.D. Monday Sept 26 2011

Monday Lectures

Combing Structure-Based Design and Mass Screening to Probe

 Ligand Binding to Integrin Receptors

Barry S. Coller  M.D.

Vice President for Medical Affairs and Physician-in-Chief

Laboratory of Blood and Vascular Biology

September 26, 2011,  Caspary Auditorium,  4 p.m.

Recommended Readings

Litvinov RI; Barsegov V; Schissler AJ; Fisher AR; Bennett JS; Weisel JW; Shuman H.  2011.  Dissociation of bimolecular αIIβ3-fibrinogen complex under a constant tensile force.   Biophysical Journal.  100(1):165-73.

Lord MS; Cheng B; McCarthy SJ; et al.  2011.  The modulation of platelet adhesion and activation by chitosan through plasma and extracellular matrix proteins.  Biomaterials. 32(28):6655-6662  (Request from Markus Library)

Blue R; Li JH; Steinberg J; et al.  2010.  Effects of limiting extension at the alpha IIb Genu on ligand binding to integrin alpha IIb beta 2.  Journal of Biological Chemistry.  285(23):17604-17613.

Sheldrake HM; Patterson LH.  2009.  Function and antagonism of beta(3) integrins in the development of cancer therapyCurrent Cancer Drug Targets. 9(4):519-540.  (Request from Markus Library)

Basani RB; Zhu H: Thornton MA: et al.  2009.  Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence difference in 2 loops of the alpha IIb beta propeller.   Blood.  113(4):902-910.

Blue R; Kowalska MA; Hirsch J; et al.  2009.  Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alpha IIb beta 3 antagonist. Blood  114(1):195-201

Blue R; Murcia M; Karan C; et al.  2008.  Application of high-throughput screening to identify a novel alpha IIb-specific small-molecule inhibitor of alpha IIb 3-mediated platelet interaction with fibrinogen.  Blood.  111(3):1248-1256.

Hynes, RO.  2002.  Integrins: bidirectional, allosteric signaling machinesCell. 110(6):673-687.